Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Other Non-Current Assets (2019 - 2025)

Avidity Biosciences' Other Non-Current Assets history spans 7 years, with the latest figure at $82.2 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 2840.07% year-over-year to $82.2 million; the TTM value through Dec 2025 reached $82.2 million, up 2840.07%, while the annual FY2025 figure was $82.2 million, 2840.07% up from the prior year.
  • Other Non-Current Assets reached $82.2 million in Q4 2025 per RNA's latest filing, down from $91.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $91.0 million in Q3 2025 to a low of $251000.0 in Q2 2021.
  • Average Other Non-Current Assets over 5 years is $9.3 million, with a median of $420000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: crashed 49.9% in 2023, then surged 28529.56% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $599000.0 in 2021, then fell by 0.17% to $598000.0 in 2022, then crashed by 49.67% to $301000.0 in 2023, then skyrocketed by 828.57% to $2.8 million in 2024, then skyrocketed by 2840.07% to $82.2 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Other Non-Current Assets are $82.2 million (Q4 2025), $91.0 million (Q3 2025), and $2.8 million (Q2 2025).